tbuckley/cabot-search huggingface dataset:
AB0578 Successful Total Hip Arthroplasty in Patients with Severe Anca- Associated Vasculitis: Single- Center Experience
Authors: T.V. Beketova, S.A. Makarov, E.I. Byalik, E.A. Naryshkin, A.L. Logunov, M.M. Lipina, A.A. Roskidaylo
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Objectives</h3> We evaluated the postoperative morbidity in patients with severe ANCA- associated vasculitis (AAV) undergoing primary total hip arthroplasty (THA). <h3>Methods</h3> Retrospective analysis of interventional case series, single referral center study. Four patients with severe AAV due to destructive hip damage (5 affected hips) were selected for 5 THA. <h3>Results</h3> The mean age of our cohort was 45 years (27- 66 years), 75% female. Two patients had microscopic polyangiitis (MPA), 1- granulomatosis with polyangiitis (GPA) and 1- eosinophilic granulomatosis with polyangiitis (EGPA). All patients had severe AAV and Five-Factor Score (FFS)=1. Short course of hemodialysis was required in one patient with MPA and rapidly progressive glomerulonephritis. In another case was the age of MPA onset &gt;65 years. The GPA patient had a history of nephrectomy for hydronephrosis, which complicated afterwards with kidney and ureter granulomatous vasculitis and occlusive thrombosis of the femoral veins in the active phase of the disease. EGPA patient was overweight (BMI 28) and had EGPA-associated cardiomyopathy. Destructive hip damage was caused by osteonecrosis in 3 patients, and fracture of the proximal femur in 1 patient with osteoporosis. At the time of THA procedure all patients were in remission phase (BVAS=0) with normal serum creatinine levels, all comorbidities were controlled by medications. In two cases AAV remission was induced by rituximab. All implants were radiographically stable without osteolysis. In all cases THA has been clinically effective, with functional gain such as improved mobility as well as pain reduction and was not associated with postoperative serious complications (except for blood transfusion requirements) or AAV relapse. <h3>Conclusions</h3> Elective THA is a safe and effective procedure for destructive hip damage in the AAV patients, including cases with the history of severe vasculitis and unfavorable prognostic factors (FFS=1). AAV remission must be achieved and comorbidities identified and treated to minimize postoperative complications. <h3>Disclosure of Interest</h3> None declared
Frequent Dysregulation of Fc Gamma Receptor IIb (Fc γRIIb) and Immunoreceptor Tyrosine-Based Inhibitory Motif (ITIM) Signaling Occurs in Multiple Myeloma (MM) Patients
Authors: Jennifer Li, Andrew Leu, Mingjie Li, Ethan D Hobel, Kevin Delijani, Joleen T Qiu, David Ramirez, Alison C Lam, Cathy Wang, Eric Sanchez, Benjamin Bonavida, Haiming Chen, James R. Berenson
Journal: Blood (2011)
AB0537 Isolated Aortitis or Aortitis Related with Retroperitoneal Fibrosis: A Single Center Experience of 12 Patients
Authors: D. Üsküdar Cansu, I. Ak Sivrikoz, M. Kebapçi, C. Korkmaz
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Aortitis is the inflammation of aortic wall and it can result from infectious or non-infectious conditions. Retroperitoneal fibrosis (RPF) may be accompanied by idiopathic aortitis. <h3>Objectives</h3> In this report, we aimed to retrospectively evaluate in terms of clinical course, treatment and outcomes of 12 patients with isolated aortitis or aortitis related with RPF. <h3>Methods</h3> We reviewed files of our patients diagnosed with non-infectious aortitis or aortitis with RPF between Jan-1998-Dec-2015. Their clinical presentations, co-morbidities, location of aortic involvement, treatment features and outcomes were recorded. The diagnosis of aortitis and RPF were based on positron emission tomography (FDG-PET-CT) scan and/or computed tomography. The presence of RPF was confirmed by biopsy in 4 patients. <h3>Results</h3> The study group consisted of 12 patients (8 M, 4 F). The mean age at the time of diagnosis was 60 yrs (42–70 yrs). Isolated aortitis was found in 5 patients, RPF plus aortitis in 6 patients, pure RPF in 1 patient. 6 patients with RPF plus aortitis presented with hydronephrosis and 1 patient with pure RPF presented with cystocele. In patients with isolated aortitis, 4 patients had subclavian and thoraco-abdominal involvement, 1 patient had bilateral subclavian and abdominal aorta involvement. 5 patients with RPF plus aortitis had only abdominal aorta involvement, 1 patient had thoraco-abdominal involvement. 1patient with abdominal aorta involvement had aortic aneurysm. Constitutional symptoms including fever, weight loss, and fatigue existed in all patients at the first admission. Hydronephrosis and post-obstructive renal failure were treated with double J stent and steroid treatment in 6 patients with RPF. Acute phase reactants increased in all patients. Ig G4 levels were determined in 8 patients and only 1 patient had increased level of Ig G4. All patients were given only prednisolone or prednisolone plus immunosuppressive drugs such as azathioprine or methotrexate. Clinical manifestations and increased acute phase reactants resolved in a reasonable time. 2 patients passed away due to sepsis and intra-cerebral infection, respectively. One of these 2 patients had many co morbidities. <h3>Conclusions</h3> While constitutional symptoms were a dominant complaint in isolated aortitis, hydronephrosis and acute renal failure as well as back pain were the chief manifestations of RPF. The presence of co-morbidities may play a role in mortality. <h3>Acknowledgement</h3> None <h3>Disclosure of Interest</h3> None declared
Impact of Comorbidities In Patients with Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML) Treated with Azacitidine (AZA)
Authors: Patricia Font, Valle Gomez Garcia De Soria, Javier Loscertales, Julio Garcia Suarez, Marta Callejas, Carmen Burgaleta, Santiago Osorio, Carlos Soto, Lucia Villalon, Jose Diez-Martin, Ana Villegas
Journal: Blood (2010)
Rituximab in Treatment-Refractory Myasthenia Gravis
Authors: Nicholas J. Silvestri, Gil I. Wolfe
Journal: JAMA Neurology (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Neurology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Neurology journal
Transcriptional Landscape of Human Tissue Lymphocytes Unveils Uniqueness of Tumor-Infiltrating T Regulatory Cells
Authors: Marco De Simone, Alberto Arrigoni, Grazisa Rossetti, Paola Gruarin, Valeria Ranzani, Claudia Politano, Raoul J.P. Bonnal, Elena Provasi, Maria Lucia Sarnicola, Ilaria Panzeri, Monica Moro, Mariacristina Crosti, Saveria Mazzara, Valentina Vaira, Silvano Bosari, Alessandro Palleschi, Luigi Santambrogio, Giorgio Bovo, Nicola Zucchini, Mauro Totis, Luca Gianotti, Giancarlo Cesana, Roberto A. Perego, Nirvana Maroni, Andrea Pisani Ceretti, Enrico Opocher, Raffaele De Francesco, Jens Geginat, Hendrik G. Stunnenberg, Sergio Abrignani, Massimiliano Pagani
Journal: Immunity (2016)
A Multi-Center, Open-Label Study To Evaluate the Safety and Efficacy of Pentostatin, Cytoxan, and Rituxan (PCR) in the Treatment of Previously Untreated or Treated, Stage III or IV, Low-Grade B-Cell Non-Hodgkin’s Lymphoma (NHL) or Bulky Stage II Lymphoma.
Authors: Raul R. Mena, Neil P. Christiansen, Yudhishtra Markan, Lalita Pandit
Journal: Blood (2007)
Fetal Hemoglobin (HbF) in Sickle Cell Anemia: Genome-Wide Association Studies Using Pooled DNA Samples Can Reveal Genetic Associations with HbF Concentration.
Authors: Paola Sebastiani, Maria M. Abad-Grau, Alberto A. Riva, Vikki G. Nolan, Efthimia Melista, Martin H. Steinberg, Clinton T. Baldwin
Journal: Blood (2006)
AB0072 Recruitment of RNA Targets by Connexin 43 RNA-Binding Motifs: Novel Mechanisms of Cellular Communication
Authors: M.D. Mayan, M. Varela-Eirin, A. Varela-Vázquez, M. Rodríguez-Candela Mateos, A. Vila-Sanjurjo, B. Acea, E. Fonseca-Capdevila
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Connexins (Cxs) are integral membrane proteins that form plasma membrane channels, allowing cell-matrix and cell to cell communication. Initially described in joining excitable cells (nerve and muscle), gap junctions (GJs) are found joining virtually all cells in solid tissues and are essential for the functional co-ordination of organs by enabling direct transfer of small signalling molecules, metabolites, ions, and electrical signals. Several studies have revealed diverse channel-independent functions of Cxs, including control of cell growth and tumorigenicity. Chondrocytes from osteoarthritic cartilage have increased expression of connexin 43 (Cx43). The myriad roles of Cx43 and its implication in the development of diseases such as cancer, osteoarthritis or alzheimer have rise to many novel questions. <h3>Objectives</h3> The aim of this study was to investigate possible RNA binding domains in the Cx43 and Cx26 sequences in order to study if cells are able to exchange molecules of RNA anchored to Cx43/Cx26 sequences present in exosomes or vesicles. <h3>Methods</h3> Amino acids sequences from Cx43 and Connexin 26 (Cx26) were obtained from the Protein Database (NCBI) and the Cx26 structure from the Protein Data Bank (RCSB) [1]. Protein sequences from both Cxs were aligned and compared with Protein Blast and Lalign servers. Analysis of RNA-binding propensity of Cx43 and Cx26 sequences was evaluated with three computational methods with the high predicting accuracy [2] aaRNA, Bind+ and Pprint. <h3>Results</h3> Protein sequences were highly conserved between Cx43 and Cx26 with the exception of the the C-terminal end (CTD). The combination of the scores obtained from the three predictors showed four domains that potentially interact with RNA sequences. Two of these domains include the intracellular loop (ICL) and the CTD. <h3>Conclusions</h3> Our results suggest that Cx43 and Cx26 are able to interact with RNA targets including siRNA and mRNA. These interactions would have a range of potential implications for cellular communication and control of signalling pathways. <h3>References</h3> Maeda S et al. Nature 458: 597–602. Nagarajan R et al. PLos ONE 9 (3): e91140. <h3>Disclosure of Interest</h3> None declared
Adenoviral Mediated TGF-β1inhibition in a Murine Model of Myelofibrosis Can Prevent and Cure Bone Marrow Fibrosis Development.
Authors: Thomas Gastinne, Orianne Wagner-Ballon, Micheline Tulliez, Hedia Chagraoui, William Vainchenker, Stephane Giraudier
Journal: Blood (2004)
Second Malignancies After Autologous Hematopoietic Cell Transplantation (AHCT) for Multiple Myeloma (MM): A Center for International Blood and Marrow Transplant Research (CIBMTR) Analysis
Authors: Girindra Raval, Anuj Mahindra, Xiaobo Zhong, Ruta Brazauskas, Robert Peter Gale, Nancy Brandenburg, Sagar Lonial, Amrita Krishnan, Angela Dispenzieri, Parameswaran Hari
Journal: Blood (2012)
Genomic Profiling of Follicular Lymphoma Identifies Novel High-Frequency Copy-Neutral Loss of Heterozygosity on Chromosomes 1p and 6p and Identifies Candidate Genes Involved in FL Biology.
Authors: Sami N. Malek, Peter D. Ouillette, Chris M. Saddler, Kerby A. Shedden, Charles W. Ross
Journal: Blood (2006)
Prognostic Value for Survival of Serum Ferritin Levels Over Time After Allogeneic Hematopoietic Cell Transplantation
Authors: Mika Nakamae, Hirohisa Nakamae, Hideo Koh, Takahiko Nakane, Mitsutaka Nishimoto, Asao Hirose, Masayuki Hino
Journal: Blood (2012)
Cost-effectiveness of PCSK9 Inhibitor Therapy—Reply
Authors: Dhruv S. Kazi, Andrew E. Moran, Kirsten Bibbins-Domingo
Journal: JAMA (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Primary Antibody Responses Against the Novel Pandemic H1N1 and Secondary Antibody Responses Against Seasonal H1N1 Can Be Induced by Vaccination In Patients Early After Allogeneic Stem Cell Transplantation
Authors: Roselke E Klinkenberg, Marieke Griffioen, Edith D van der Meijden, Erik W.A. Marijt, J.H. Frederik Falkenburg
Journal: Blood (2010)
The Addition of Radiation Therapy to Initial Treatment for Extramedullary Acute Myeloid Leukemia Does Not Offer a Survival Benefit When Added to Chemotherapy
Authors: Faye M. Feller, Minal Patel, Sean M. Devlin, Molly Maloy, Martin S. Tallman, Miguel-Angel Perales, Raajit K. Rampal
Journal: Blood (2014)
Clustering Adult ACUTE Lymphoblastic Leukemia (ALL) Philadelphia Negative (Ph-) By Whole Exome Sequencing (WES) Analysis
Authors: Anna Ferrari, Andrea Ghelli Luserna Di Rora, Italo Do Valle, Marianna Garonzi, Valentina Robustelli, Jesus Maria Hernandez-Rivas, Alessandra Santoro, Sarka Pospisilova, Torsten Haferlach, Antonella Padella, Giorgia Simonetti, Cristina Papayannidis, Maria Chiara Abbenante, Marco Sazzini, Alberto Ferrarini, Julien Schira, Massimo Delledonne, Gastone Castellani, Daniel Remondini, Giovanni Martinelli
Journal: Blood (2015)
Nilotinib, in Comparison to Both Dasatinib and Imatinib, Possesses a Greatly Prolonged Residence Time When Bound to the BCR-ABL Kinase SH1 Domain
Authors: Paul W. Manley, Sandra W. Cowan-Jacob, Gabriele Fendrich, Wolfgang Jahnke, Doriano Fabbro
Journal: Blood (2011)
Biological Rationale for the Favorable Clinical Outcomes of Patients Carrying SF3B1 Mutations in Myelodysplastic Syndromes with Ring Sideroblasts
Authors: Valeria Visconte, Reda Z Mahfouz, Ali Tabarroki, Heesun J. Rogers, Bodo Juraj, Edy Hasrouni, Reza Sharghi-Moshtaghin, Nanthawan Avishai, Manoj Bupathi, Betty K. Hamilton, Yang Liu, Hideki Makishima, Anna Jankowska, John Barnard, Fabiola Traina, Yogen Saunthararajah, Edward A. Copelan, Arthur Heuer, Daniel Lindner, Jaroslaw P. Maciejewski, Mikkael A. Sekeres, Ramon V. Tiu
Journal: Blood (2012)
Microrna-16 Mediates the Regulation of a Senescence-Apoptosis Switch in Cutaneous T-Cell and Other Non-Hodgkin Lymphomas
Authors: Akihiro Kitadate, Sho Ikeda, Kazuaki Teshima, Mitsugu Ito, Naoto Takahashi, Tomomitsu Miyagaki, Makoto Sugaya, Hiroyuki Tagawa
Journal: Blood (2015)
ATPS-27SIMULTANEOUS TARGETING OF THE CELL CYCLE AND GLOBAL TRANSCRIPTION BY IRREVERSIBLE INHIBITION OF CDK7 AS A NOVEL THERAPEUTIC APPROACH FOR HIGH-GRADE GLIOMA
Authors: Sameer Greenall, Terrance Johns
Journal: Neuro-Oncology (2015)

High-grade glioma (HGG) is an aggressive brain neoplasm that is incurable. Targeted therapies are promising replacements or adjuncts to traditional therapies but have so far been unsuccessful. One problem is that HGG is characterised by a diverse range of genetic aberrations, including in the receptor tyrosine kinase (RTK) signalling and cell cycle regulation pathways, which drive tumor proliferation and survival. Another is that HGG has a highly heterogeneous intratumoral transcriptional profile allowing adaptation to a range of therapeutics. Cyclin dependent kinase 7 (CDK7) presents an opportunity to simultaneously target proliferation to prevent tumor growth and global transcription to prevent transcriptional adaptation to therapy, as this enzyme forms the CDK activating kinase that controls progression through multiple checkpoints in the cell cycle and also stabilises the RNA polymerase II-based transcriptional apparatus needed for efficient gene transcription. Using a new and irreversible inhibitor of CDK7, THZ1, we demonstrate that a panel of 10 patient-derived primary gliomaspheres, representing a diverse range of genotypes and phenotypes, were all highly sensitive to THZ1 treatment, with IC50 values of <100 nM. THZ1 induced global transcription downregulation, as determined by microarray analysis, and resulted in potent caspase 3/7 activation and apoptosis. In all gliomaspheres, the cell cycle was arrested at the G2/M phase regardless of TP53, CDKN2A/B or RB status, with substantial aneuploidy observed, a trait linked to the decreased stability of the anti-apoptotic protein survivin. THZ1 treatment resulted in a loss of total and cell surface expression of several RTKs critical to driving gliomagenesis, including EGFR, EGFRvIII, PDGFR-α, PDGFR-β, MET, FGFR3 and AXL. This resulted in a marked reduction in PI3K/AKT, MAPK/ERK and STAT3 activation, regardless of PTEN, PI3K or RAS status. In vivo orthograft experiments will also be presented. These findings suggest that irreversible inhibition of CDK7 is a novel and effective treatment for HGG.
Venous Thromboembolism (VTE) Prevention with Semuloparin in Cancer Patients Initiating Chemotherapy: Benefit-Risk Assessment by VTE Risk in SAVE-ONCO
Authors: Daniel George, Giancarlo Agnelli, William Fisher, Ajay Kakkar, Michael R Lassen, Patrick Mismetti, Patrick Mouret, Francesca Lawson, Alexander G.G. Turpie
Journal: Blood (2011)
VITAMIN D Insufficiency Affects Time to FIRST TREATMENT (TFT) In EARLY CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)
Authors: Stefano Molica, Giovanna Digiesi, Anna Antenucci, Luciano Levato, Rosanna Mirabelli, Massimo Gentile, Diana Giannarelli, Isabella Sperduti, Fortunato Morabito, Laura Conte
Journal: Blood (2011)
Outcome of Patients with Beta-Thalassemia Major Given Either Bone Marrow and Frozen Cord Blood of Same Sibling or Bone Marrow Transplantation from Sibling Donors
Authors: Xuedong Wu, Jianyun Wen, Pei Fuyu, Libai Chen, Jianyun Liao, Yuelin He, Qi Li, Yongsheng Ruan, Chunfu Li
Journal: Blood (2014)
First Interim Safety Analysis of a Phase III Randomized Trial in Newly Diagnosed Systemic Peripheral T-Cell Lymphoma Treated with CHOP Chemotherapy with or without Alemtuzumab and Consolidated by Autologous Hematopoietic Stem Cell Transplant,
Authors: Francesco d'Amore, Maria Gomes da Silva, Sirpa Leppa, Thomas Relander, Antonio Pezzutto, Grete F. Lauritzsen, Eckhart Weidmann, Michel Van Gelder, Mats Merup, Hans Hagberg, Unn-Merete Fagerli, Peter de Nully Brown, Per Boye Hansen, Jose Mario Mariz, Milada Jankovska, Jan Walewski, Jeanette Doorduijn, Achiel Van Hoof, Ilse Christiansen, Sirkku Jyrkkiö, J.C. Kluin-Nelemans, Marinus van Marwijk Kooy, Rob Fijnheer, Wendy Stevens, Josee Zijlstra, L. Böhmer, P.J. Lugtenburg, Matthias Grube, Vit Prochazka, David Salek, Richard Greil, Lorenz Trümper, Gerald Wulf, Bettina Altmann, Marita Ziepert, Markus Loeffler, Esa Jantunen, Georg Hopfinger, Eric Van den Neste, Helle Toldbod
Journal: Blood (2011)
PTU-058 Colon Capsule Endoscopy: A Useful Tool in the Diagnosis and Management of Inflammatory Bowel Disease: Abstract PTU-058 Table 1
Authors: JL Cook, MF Hale, K Drew, R Sidhu, ME McAlindon
Journal: Gut (2016)

<h3>Introduction</h3> Colon capsule endoscopy (CCE) is a novel non-invasive means of directly imaging the colonic mucosal surface. Limited data is available regarding the utility of CCE in the diagnosis and re-assessment of inflammatory bowel disease (IBD), but it is attractive to patients due to its non-invasive nature and ability to obtain small bowel and pan-colonic images. We present a large series of patients with known or suspected IBD undergoing CCE. <h3>Methods</h3> Retrospective, single-centre, including 193 patients with known or suspected IBD attending for CCE using PillCam Colon (Given Imaging, Israel). All patients known to have IBD successfully passed a PillCam Patency device prior. Demographical and procedural data was collated together with final diagnosis and management outcome. <h3>Results</h3> Mean age 38.8 years (range 17–82), 129 female, median follow-up 43 months (range 3–99). 71 chose CCE over colonoscopy, 66 refused colonoscopy, 49 had an incomplete colonoscopy, and 7 were unfit for colonoscopy. Indication for the procedure: known IBD (n = 66, 5 with ulcerative colitis, 61 with Crohn’s disease) of which 30 patients were undergoing CCE for disease re-assessment after 12 months of anti-TNF therapy and 36 due to a relapse in symptoms. The remaining 127 had suspected IBD. Procedure completion rate 75.5%, bowel preparation was good or adequate in 64.3%. There were no adverse events. In the known IBD group, 45 patients were diagnosed with active disease based on the CCE findings. This lead to changes in management in 44 patients (67%); mainly in the form of medication alteration (40 patients), but also by further investigation (4 patients). In the suspected IBD group, CCE diagnostic yield for IBD was 6%, 5 patients were diagnosed with Crohn’s disease and 2 patients were diagnosed with ulcerative colitis. In the group with small bowel inflammation 1 patient was diagnosed with NSAID related enteropathy and 1 had non-specific histology and is undergoing further investigation. Other clinically relevant alternative findings are outlined in <i>Table 1</i>. Overall CCE made 37 clinically significant diagnoses in the small bowel rather than the colon; 27 in the known IBD group and 10 in the suspected IBD group. Abbreviations: IBD=inflammatory bowel disease <h3>Conclusion</h3> CCE is a useful patient friendly alternative for the diagnosis and re-assessment of patients with known or suspected IBD and impacts management. The distal small bowel is visualised with excellent clarity making CCE particularly useful for those with suspected or known ileocolonic disease. <h3>Disclosure of Interest</h3> None Declared